Search results for "lignan"

showing 10 items of 613 documents

Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth

2018

Fibrosarcomas are soft tissue mesenchymal tumors originating from transformed fibroblasts. Fibroblast growth factor-2 (FGF2) and its tyrosine-kinase receptors (FGFRs) play pivotal roles in fibrosarcoma onset and progression, FGF2 being actively produced by fibroblasts in all stages along their malignant transformation to the fibrosarcoma stage. The soluble pattern recognition receptor long pentraxin-3 (PTX3) is an extrinsic oncosuppressor whose expression is reduced in different tumor types, including soft tissue sarcomas, via hypermethylation of its gene promoter. PTX3 interacts with FGF2 and other FGF family members, thus acting as a multi-FGF antagonist able to inhibit FGF-dependent neov…

0301 basic medicineCancer ResearchFGF; FGF-trap; FGFR; fibrosarcoma; long pentraxin-3Fibroblast growth factorlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinemedicineFGFFibrosarcomaFibroblastReceptorneoplasmsOriginal ResearchFGF-trapintegumentary systemChemistryFGFRMesenchymal stem cellPTX3medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structurelong pentraxin-3OncologyFibroblast growth factor receptor030220 oncology & carcinogenesisCancer researchfibrosarcomaFrontiers in Oncology
researchProduct

Potential of induced metabolic bioluminescence imaging to uncover metabolic effects of antiangiogenic therapy in tumors

2016

Tumor heterogeneity at the genetic level has been illustrated by a multitude of studies on the genomics of cancer, but whether tumors can be heterogeneous at the metabolic level is an issue which has been less systematically investigated so far. A burning related question is whether the metabolic features of tumors can change either following natural tumor progression (i.e. in primary tumors versus metastasis) or therapeutic interventions. In this regard, recent findings by independent teams indicate that anti-angiogenic drugs cause metabolic perturbations in tumors as well as metabolic adaptations associated with increased malignancy. Induced metabolic bioluminescence imaging (imBI) is an …

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtyAngiogenesisMini ReviewBiologyMalignancylcsh:RC254-282MetastasisImaging03 medical and health sciencesAngiogenesis; Cancer mouse models; Glycolysis; Imaging; MetabolismmedicineBioluminescence imagingGlycolysismouse modelsCancerCancerMetabolismlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyMetabolismOncologyTumor progressionCancer researchAngiogenesisGlycolysis
researchProduct

Normal vs cancer thyroid stem cells: the road to transformation

2015

Recent investigations in thyroid carcinogenesis have led to the isolation and characterisation of a subpopulation of stem-like cells, responsible for tumour initiation, progression and metastasis. Nevertheless, the cellular origin of thyroid cancer stem cells (SCs) remains unknown and it is still necessary to define the process and the target population that sustain malignant transformation of tissue-resident SCs or the reprogramming of a more differentiated cell. Here, we will critically discuss new insights into thyroid SCs as a potential source of cancer formation in light of the available information on the oncogenic role of genetic modifications that occur during thyroid cancer develop…

0301 basic medicineCancer ResearchThyroid GlandBiologymedicine.disease_causeMalignant transformationMetastasis03 medical and health sciencesSettore MED/04 - PATOLOGIA GENERALECancer stem cellGeneticsmedicineHumansThyroid Neoplasmsthyroid stem cellsMolecular BiologyThyroid cancerThyroidCancerThyroid Cancer Stem Cells Cancer Stem Cells Oncogenes Metastasismedicine.diseaseCell Transformation Neoplastic030104 developmental biologymedicine.anatomical_structureImmunologyNeoplastic Stem CellsCancer researchStem cellCarcinogenesisOncogene
researchProduct

More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study

2021

BackgroundThe aim of the study was to compare coronavirus disease 2019 (COVID-19) severity presentation between oncologic and non-oncologic patients and to evaluate the impact of cancer type and stage on COVID-19 course.MethodsWe performed a multicentre, retrospective study involving 13 COVID-19 Units in Campania region from February to May 2020. We defined as severe COVID-19 presentation the cases that required mechanical ventilation and/or admission to Intensive Care Units (ICU) and/or in case of death.ResultsWe enrolled 371 COVID-19 patients, of whom 34 (9.2%) had a history or a diagnosis of cancer (24 solid, 6 onco-hematological). Oncologic patients were older (p<0.001), had more…

0301 basic medicineCancer Researchmedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentoncologic patientseverity diseaseactive cancerMalignancy03 medical and health sciences0302 clinical medicineIntensive careInternal medicinemedicineStage (cooking)RC254-282Original ResearchMechanical ventilationSARS-CoV-2business.industryCOVID-19Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancerRetrospective cohort studymedicine.diseaseoncologic patients030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessCohort studyFrontiers in Oncology
researchProduct

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies

2021

Simple Summary Childhood cancers are mostly of unknown etiology and represent devastating diagnoses. The clinical benefits of steadily increasing tumor control and survival rates are countered by severe and fatal health consequences from genotoxic therapies in long-term survivors of pediatric cancers. Among them, iatrogenic second primary malignancies represent the heaviest burden for the patient. Therefore, particularly in pediatric tumor patients, the reduction of genotoxic treatments and the use of targeted or immune-based oncologic strategies are of high clinical interest. The knowledge of therapy-associated as well as intrinsic risk factors for late sequelae of antineoplastic treatment…

0301 basic medicineCancer Researchmedicine.medical_specialtyetiologymedicine.medical_treatmentPopulationReviewchemotherapyTargeted therapy03 medical and health sciences0302 clinical medicineEpidemiologymedicinechildhood cancerlate-effectseducationIntensive care medicineradiotherapyRC254-282education.field_of_studyChemotherapybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyPediatric cancerRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisEtiologyepidemiologyimmunotherapybusinesssecond primary malignancyCancers
researchProduct

[1,2]Oxazolo[5,4-e]isoindoles as promising tubulin polymerization inhibitors

2016

Abstract A series of [1,2]Oxazolo [5,4- e ]isoindoles has been synthesized through a versatile and high yielding sequence. All the new structures showed in the 1 HNMR spectra, the typical signal in the 8.34–8.47 ppm attributable to the H-3 of the [1,2]oxazole moiety. Among all derivatives, methoxy benzyl substituents at positions 3 and 4 or/and 5 were very effective in reducing the growth of different tumor cell lines, including diffuse malignant peritoneal mesothelioma (DMPM), an uncommon and rapidly malignancy poorly responsive to available therapeutic options. The most active compound 6j was found to impair tubulin polymerization, cause cell cycle arrest at G2/M phase and induce apoptosi…

0301 basic medicineCell cycle checkpointIsoindoles2]Oxazolo[5StereochemistryDiffuse malignant peritoneal mesotheliomaα-hydroxyalkyl ketonesAntineoplastic AgentsApoptosisIsoindoles01 natural sciencesTubulin Polymerization Inhibitors03 medical and health scienceschemistry.chemical_compoundIsomerismTubulinCell Line TumorDrug DiscoveryHumansMoietyProtein Structure QuaternaryOxazole[12]Oxazolo[54-e]isoindolePharmacology010405 organic chemistryChemistryAntitubulin agentsDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryGeneral MedicineSettore CHIM/08 - Chimica FarmaceuticaTubulin Modulators0104 chemical sciencesAntitubulin agentG2 Phase Cell Cycle Checkpointsα-hydroxyalkyl ketone030104 developmental biologyApoptosisActive compound4-e]isoindolesProton NMRM Phase Cell Cycle CheckpointsAntitubulin agents; Diffuse malignant peritoneal mesothelioma; [1; 2]Oxazolo[5; 4-e]isoindoles; α-hydroxyalkyl ketones; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry[1Drug Screening Assays AntitumorProtein Multimerization
researchProduct

Role of TCTP for Cellular Differentiation and Cancer Therapy

2017

The translationally controlled tumor protein (TCTP) is a highly conserved protein that is regulated due to a high number of extracellular stimuli. TCTP has an important role for cell cycle and normal development. On the other side, tumor reversion and malignant transformation have been associated with TCTP. TCTP has been found among the 12 genes that are differentially expressed during mouse oocyte maturation, and an overexpression of this gene was reported in a wide variety of different cancer types. Its antiapoptotic effect is indicated by the interaction with several proapoptotic proteins of the Bcl-2 family and the p53 tumor suppressor protein. In this article, we draw attention to the …

0301 basic medicineCell growthCellular differentiationCancerBiologyCell cyclemedicine.diseaseMalignant transformation03 medical and health sciences030104 developmental biology0302 clinical medicineDifferentiation therapy030220 oncology & carcinogenesisCancer cellTranslationally-controlled tumor proteinmedicineCancer research
researchProduct

IL‐10‐producing B cells are characterized by a specific methylation signature

2019

Among the family of regulatory B cells, the subset able to produce interleukin-10 (IL-10) is the most studied, yet its biology is still a matter of investigation. The DNA methylation profiling of the il-10 gene locus revealed a novel epigenetic signature characterizing murine B cells ready to respond through IL-10 synthesis: a demethylated region located 4.5 kb from the transcription starting site (TSS), that we named early IL10 regulatory region (eIL10rr). This feature allows to distinguish B cells that are immediately prone and developmentally committed to IL-10 production from those that require a persistent stimulation to exert an IL-10-mediated regulatory function. These late IL-10 pro…

0301 basic medicineChronic lymphocytic leukemiaRegulatory B cellsImmunologyB-Lymphocyte SubsetsLymphoma Mantle-CellRegulatory Sequences Nucleic AcidBiologyLymphocyte ActivationB-cell malignanciesMice03 medical and health scienceschemistry.chemical_compoundInterleukin 100302 clinical medicineTranscription (biology)Immune ToleranceTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyB cells; B-cell malignancies; DNA methylation; epigenetics; Interleukin 10; Immunology and Allergy; ImmunologyEpigeneticsB-Lymphocytes RegulatoryB cellsB cellDNA methylationepigeneticsGene Expression ProfilingB cells; B-cell malignancies; DNA methylation; epigenetics; Interleukin 10Cell DifferentiationMethylationmedicine.diseaseLeukemia Lymphocytic Chronic B-CellImmunity HumoralInterleukin-10Cell biologyMice Inbred C57BLInterleukin 10030104 developmental biologychemistryDNA methylationB-cell malignancieFemaleepigeneticDNA030215 immunologyEuropean Journal of Immunology
researchProduct

Harnessing the potential of noninvasive in vivo preclinical imaging of the immune system: challenges and prospects.

2016

Preclinical imaging has become a powerful method for investigation of in vivo processes such as pharmacokinetics of therapeutic substances and visualization of physiologic and pathophysiological mechanisms. These are important aspects to understand diseases and develop strategies to modify their progression with pharmacologic interventions. One promising intervention is the application of specifically tailored nanoscale particles that modulate the immune system to generate a tumor targeting immune response. In this complex interaction between immunomodulatory therapies, the immune system and malignant disease, imaging methods are expected to play a key role on the way to generate new thera…

0301 basic medicineFluorescence-lifetime imaging microscopyTumor targetingBiomedical EngineeringMedicine (miscellaneous)Contrast MediaBioengineeringDevelopmentBiologyPharmacologic interventionMalignant diseaseImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemIn vivoNeoplasmsBioluminescence imagingAnimalsHumansGeneral Materials ScienceOptical ImagingMagnetic Resonance Imaging030104 developmental biology030220 oncology & carcinogenesisImmune SystemPositron-Emission TomographyImmunologyDisease ProgressionNeurosciencePreclinical imagingNanomedicine (London, England)
researchProduct

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

2020

Prodigiosin, a bioactive secondary metabolite produced by Serratia marcescens, is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelia…

0301 basic medicineHistologylcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyhalloysite nanotubesengineering.materialHalloysiteProdigiosin03 medical and health scienceschemistry.chemical_compoundcomet assaylcsh:TP248.13-248.65Cytotoxic T cellcancerOriginal Researchgenotoxic effectanti-cancer drugsbiologyChemistryBioengineering and Biotechnology021001 nanoscience & nanotechnologybiology.organism_classificationmalignant cellsComet assay030104 developmental biologyprodigiosinDrug deliveryToxicitySerratia marcescensdrug deliveryCancer researchengineering0210 nano-technologyDrug carrierBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct